医药生物行业报告（2026.3.2-2026.3.6）：聚焦两会：打造生物医药等新兴支柱产业，健全医疗保障体系，推动商保和创新发展

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" [1] Core Insights - The report highlights the government's focus on strengthening basic medical services and promoting the biopharmaceutical industry as a key emerging sector during the 2026 National People's Congress [4][16] - It is anticipated that policy guidance will lead to increased capital support for pharmaceutical supply-side innovations, enhancing the global competitiveness of domestic innovative drug companies [5][20] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8092.32, with a 52-week high of 9323.49 and a low of 6876.88 [1] Market Performance - The A-share pharmaceutical and biotechnology sector fell by 2.78% from March 2 to March 6, 2026, underperforming the CSI 300 index by 1.71 percentage points [6][21] - The sector's performance ranked 17th among 31 sub-industries during the week [6] Investment Recommendations 1. Innovative Drugs and Industry Chain: - The report suggests a stable funding environment for innovative drugs, with a focus on companies like Innovent Biologics, 3SBio, and others [7][24] - The report emphasizes the increasing global participation of domestic innovative drugs, predicting a harvest period for new drugs in the medium term [24] 2. CXO and Life Science Services: - Investment opportunities are seen in CXO and life science service companies due to a stable recovery in overseas R&D and production outsourcing demand [8][25] 3. Medical Devices: - The medical device sector is expected to see a turnaround as the pressure from centralized procurement diminishes, with leading companies showing improved performance [28] 4. Traditional Chinese Medicine: - The report highlights opportunities in traditional Chinese medicine, particularly those benefiting from basic drug policies and innovation [31][32] 5. AI in Healthcare: - AI technology is expected to enhance drug development efficiency and diagnostic accuracy, with several companies identified as potential beneficiaries [36] Sector Valuation - As of March 6, 2026, the overall valuation of the pharmaceutical sector is 30.45, with a valuation premium of 125.07% over the CSI 300 index [43]